Diabetes researchers set up company to develop RAGE-targeted products

Diabetes researchers have set up a commercial venture to develop new anti-inflammatory therapies based on the concept of modulating the receptor for advanced glycation end-products (RAGE). RAGE Biotech is an Australian company aiming to develop new therapies to treat conditions such as diabetes, atherosclerosis and lung disease based on RAGE research by clinicians such as ...

Already a member?

Login to keep reading.

© 2021 the limbic